Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Scilex Holding Company

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PALO ALTO, CALIF., NOV. 26, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, ANNOUNCED TODAY THAT IT HAS CLOSED THE SECOND TRANCHE OF ITS STRATEGIC INVESTMENT IN DATAVAULT AI IN BTC (BASED ON THE SPOT EXCHANGE RATE OF BTC AS OF THE SIGNING OF THE STRATEGIC INVESTMENT). THE CLOSING OF THIS SECOND TRANCHE FOLLOWED THE APPROVAL BY THE DATAVAULT STOCKHOLDERS AT DATAVAULT'S NOVEMBER 24, 2025 ANNUAL MEETING OF THE ISSUANCE OF THE SHARES OF DATAVAULT COMMON STOCK UPON EXERCISE OF THE PRE-FUNDED WARRANT. SCILEX'S SHARES OF DATAVAULT COMMON STOCK ISSUED UPON THE EXERCISE IN FULL OF THE PRE-FUNDED WARRANT HAVE AN APPROXIMATE VALUE OF $583.3 MILLION BASED ON THE CLOSING PRICE OF $2.21 PER SHARE OF DATAVAULT AI COMMON STOCK ON THE NASDAQ CAPITAL MARKET ON NOVEMBER 25, 2025.

SCILEX HOLDING COMPANY ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED SECOND TRANCHE INVESTMENT IN DATAVAULT AI INC., COMPLETING ITS TWO-TRANCHE EQUITY FINANCING IN DATAVAULT AI INC.

SECOND TRANCHE CLOSING OF APPROXIMATELY 1,237.6 BITCOIN FOLLOWS APPROVAL BY DATAVAULT AI'S STOCKHOLDERS AT ANNUAL MEETING. SCILEX HOLDING COMPANY PURCHASED A PRE-FUNDED WARRANT EXERCISABLE FOR APPROXIMATELY 263.91 MILLION SHARES OF DATAVAULT AI COMMON STOCK IN CONNECTION WITH THE CLOSING OF THIS SECOND TRANCHE.

DATAVAULT AI ANNOUNCES CLOSING OF THE SECOND TRANCHE OF SCILEX HOLDING COMPANY'S PREVIOUSLY ANNOUNCED EQUITY FINANCING

PALO ALTO, CALIF., NOV. 25, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, ANNOUNCED TODAY THE CLOSING OF ITS PREVIOUSLY ANNOUNCED EXERCISE OF CERTAIN EXISTING WARRANTS TO PURCHASE AN AGGREGATE OF (I) 428,572 SHARES OF COMMON STOCK (THE COMMON STOCK) HAVING AN EXERCISE OF $38.50 PER SHARE AND ISSUED IN APRIL 2024 (THE APRIL 2024 WARRANTS) AND (II) 475,824 SHARES OF COMMON STOCK HAVING AN EXERCISE PRICE OF $22.72 PER SHARE AND ISSUED IN DECEMBER 2024 (TOGETHER WITH THE APRIL 2024 WARRANTS, THE EXISTING WARRANTS) AT A REDUCED EXERCISE PRICE OF $22.51 PER SHARE. THE AGGREGATE GROSS PROCEEDS FROM THE EXERCISE OF THE EXISTING WARRANTS WERE APPROXIMATELY $20.3 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES PAYABLE BY THE COMPANY.

SCILEX HOLDING COMPANY ANNOUNCES CLOSING OF EXERCISE OF WARRANTS FOR $20.3 MILLION GROSS PROCEEDS

PALO ALTO, CALIF., NOV. 24, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, ANNOUNCED TODAY THAT IT HAS ENTERED INTO A DEFINITIVE AGREEMENT FOR THE EXERCISE OF CERTAIN EXISTING WARRANTS TO PURCHASE AN AGGREGATE OF (I) 428,572 SHARES OF COMMON STOCK (THE COMMON STOCK) HAVING AN EXERCISE OF $38.50 PER SHARE AND ISSUED IN APRIL 2024 (THE APRIL 2024 WARRANTS) AND (II) 475,824 SHARES OF COMMON STOCK HAVING AN EXERCISE PRICE OF $22.72 PER SHARE AND ISSUED IN DECEMBER 2024 (TOGETHER WITH THE APRIL 2024 WARRANTS, THE EXISTING WARRANTS).

SCILEX HOLDING COMPANY ANNOUNCES EXERCISE OF WARRANTS FOR $20.3 MILLION GROSS PROCEEDS

PALO ALTO, CALIF., NOV. 21, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, ANNOUNCED TODAY THAT, WITH RESPECT TO THE VOLUNTARY DISTRIBUTION BY DATAVAULT AI INC. (DATAVAULT AI) (NASDAQ: DVLT) OF DREAM BOWL 2026 MEME COINS TO RECORD HOLDERS OF SCILEX COMMON STOCK, GIVEN THAT SUCH DISTRIBUTION IS BEING MADE BY DATAVAULT AI AS A TOKEN OF ITS APPRECIATION FOR SCILEX'S RELATIONSHIP WITH DATAVAULT AI AS A STOCKHOLDER OF DATAVAULT AI, LICENSING PARTNER AND CO-SPONSOR OF THE DREAM BOWL XIV EVENT TO BE HELD ON JANUARY 11, 2026, NASDAQ HAS INFORMED DATAVAULT AI THAT IT IS NOT PLANNING TO MAKE ANY ANNOUNCEMENT FOR SCILEX REGARDING SUCH DISTRIBUTION, WHETHER AS TO THE RECORD DATE OR AN EX-DIVIDEND DATE. NOTWITHSTANDING THE ABSENCE OF SUCH ANNOUNCEMENT, DATAVAULT AI HAS INFORMED THE COMPANY THAT IT INTENDS TO MAKE SUCH VOLUNTARY DISTRIBUTION TO RECORD HOLDERS OF SCILEX COMMON STOCK AS OF NOVEMBER 25, 2025 CONCURRENTLY WITH THE DISTRIBUTION OF THE DREAM BOWL 2026 MEME COINS TO DATAVAULT AI'S ELIGIBLE RECORD EQUITY HOLDERS, INCLUDING THE COMPANY.

SCILEX HOLDING COMPANY ANNOUNCES UPDATE REGARDING DISTRIBUTION OF DREAM BOWL 2026 MEME COIN BY DATAVAULT AI INC.

PALO ALTO, CALIF., NOV. 11, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS OF DATAVAULT AI INC. (DATAVAULT AI) (NASDAQ: DVLT) HAS APPROVED THE DISTRIBUTION OF A DREAM BOWL 2026 MEME COIN TO ALL [ELIGIBLE] SCILEX AND DATAVAULT AI STOCKHOLDERS OF RECORD AND SET A RECORD DATE OF NOVEMBER 25, 2025 FOR DETERMINING STOCKHOLDERS ENTITLED TO RECEIVE THE DREAM BOWL 2026 MEME COIN FROM DATAVAULT AI.

SCILEX HOLDING COMPANY ANNOUNCES THAT THE BOARD OF DIRECTORS OF DATAVAULT AI INC. HAS APPROVED THE DISTRIBUTION OF A DREAM BOWL 2026 MEME COIN TO ALL ELIGIBLE SCILEX AND DATAVAULT AI STOCKHOLDERS OF RECORD AND SET A RECORD DATE OF NOVEMBER 25, 2025

PHILADELPHIA, NOV. 10, 2025 (GLOBE NEWSWIRE) -- VIA IBN  DATAVAULT AI INC. (NASDAQ: DVLT), A LEADER IN DATA MONETIZATION, CREDENTIALING, AND DIGITAL ENGAGEMENT TECHNOLOGIES, TODAY RELEASED AN INVESTOR UPDATE DETAILING KEY DEVELOPMENTS ACROSS ITS FINANCIAL PERFORMANCE, TECHNOLOGY PLATFORMS, AND INTERNATIONAL FOOTPRINT AS THE COMPANY CONTINUES TO EXPAND ITS PRESENCE IN THE GLOBAL PROOF ECONOMY. DATAVAULT'S RECENT PROGRESS REFLECTS ITS COMMITMENT TO CREATING MEASURABLE SHAREHOLDER VALUE THROUGH INNOVATION, PARTNERSHIPS, AND VERIFIED GROWTH.

DATAVAULT AI INC. (NASDAQ: DVLT) ISSUES INVESTOR UPDATE HIGHLIGHTING CONTINUED REVENUE GROWTH, STRATEGIC PARTNERSHIPS, AND GLOBAL EXPANSION

PHILADELPHIA, NOV. 04, 2025 (GLOBE NEWSWIRE) -- VIA IBN -- DATAVAULT AI INC. (DATAVAULT AI OR THE COMPANY) (NASDAQ: DVLT), A LEADER IN AI-DRIVEN BLOCKCHAIN SOLUTIONS FOCUSING ON DATA MONETIZATION, ASSET TOKENIZATION, AND SECURE DIGITAL MARKETPLACES, TODAY ANNOUNCED THAT IT HAS GRANTED A WORLDWIDE EXCLUSIVE LICENSE, WITH THE RIGHT TO SUBLICENSE, TO SCILEX HOLDING COMPANY (NASDAQ: SCLX), FOR DATAVAULT AI'S PROPRIETARY AI-DRIVEN TECHNOLOGY. THIS LICENSE IS TAILORED FOR USE WITHIN THE BIOTECH AND BIOPHARMA INDUSTRY, ENABLING SCILEX TO CREATE AND OPERATE A BIOTECH EXCHANGE PLATFORM. BY LEVERAGING DATAVAULT AI'S ADVANCED DATA PLATFORMS, SCILEX CAN FACILITATE SECURE TOKENIZATION, TRADING, AND MONETIZATION OF BIOTECH ASSETS, INCLUDING GENOMIC AND DNA DATA, DIAGNOSTIC AND THERAPEUTIC PRODUCTS, GENETIC INFORMATION, AND DRUG DATA. THIS AGREEMENT REPRESENTS A MAJOR ADVANCEMENT IN COMMERCIALIZING BIOTECH INNOVATIONS AND BUILDS DIRECTLY ON DATAVAULT AI'S ESTABLISHED EXPERTISE IN HIGH-PERFORMANCE COMPUTING AND DATA-DRIVEN SOLUTIONS.

DATAVAULT AI INC. ANNOUNCES A $10M WORLDWIDE EXCLUSIVE LICENSE AGREEMENT WITH SCILEX HOLDING COMPANY FOR TOKENIZATION AND MONETIZATION OF REAL-WORLD ASSETS (RWA) IN GENOMIC, DNA DATA, DIAGNOSTICS, THERAPEUTICS, GENETIC, AND DRUG INFORMATION

PALO ALTO, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT HAS IN-LICENSED A WORLDWIDE EXCLUSIVE LICENSE, WITH RIGHT TO SUBLICENSE, TO DATAVAULT AI'S PROPRIETARY AI-DRIVEN TECHNOLOGY FOR THE USE WITHIN THE BIOTECH AND BIOPHARMA INDUSTRY, SPECIFICALLY ENABLING THE CREATION AND OPERATION OF A BIOTECH EXCHANGE PLATFORM. THIS LICENSE ALLOWS SCILEX TO LEVERAGE DATAVAULT AI'S ADVANCED DATA PLATFORMS FOR SECURE TOKENIZATION, TRADING, AND MONETIZATION OF BIOTECH ASSETS, INCLUDING GENOMIC, DNA DATA, DIAGNOSTIC, THERAPEUTIC PRODUCTS, GENETIC AND DRUG INFORMATION, MARKING A SIGNIFICANT STEP FORWARD IN THE COMMERCIALIZATION OF BIOTECH INNOVATIONS.

SCILEX HOLDING COMPANY ANNOUNCES WORLDWIDE EXCLUSIVE LICENSE FOR TOKENIZATION AND MONETIZATION OF REAL-WORLD ASSET (RWA) IN GENOMIC, DNA DATA, DIAGNOSIS, THERAPEUTICS PRODUCTS, GENETIC AND DRUG INFORMATION FROM DATAVAULT AI

PALO ALTO, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT IT IS SPONSORING THE DREAM BOWL 2026 AND SET A RECORD DATE OF NOVEMBER 14, 2025 FOR ITS SHAREHOLDERS TO RECEIVE DREAM BOWL 2026 MEME COIN, WHICH WILL BE DISTRIBUTED BY DATAVAULT AI.

SCILEX HOLDING COMPANY ANNOUNCES THE SPONSORSHIP OF DREAM BOWL 2026 AND SET A RECORD DATE OF NOVEMBER 14, 2025 FOR ITS SHAREHOLDERS TO RECEIVE DREAM BOWL 2026 MEME COIN DISTRIBUTED BY DATAVAULT AI

PHILADELPHIA, NOV. 03, 2025 (GLOBE NEWSWIRE) -- VIA IBN -- DATAVAULT AI INC. (NASDAQ: DVLT), A PIONEER IN AI-POWERED DATA VALUATION AND TOKENIZATION, TODAY UNVEILED PLANS FOR THE HIGHLY ANTICIPATED DREAM BOWL DRAFT, SET TO SELECT TOP INVITEES FOR THE CRUSADERS VS. PATRIOTS MATCHUP IN THE 2026 DREAM BOWL PRESENTED BY SCILEX (NASDAQ: SCLX).

Scilex Holding Company

SCLX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Scilex Holding Company

SCLX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SCLX